[1] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4):271-289.
[2] Advani S, Parikh P, Patil V, et al. Guidelines for treatment of recurrent or metastatic head and neck cancer[J]. Indian J Cancer, 2014, 51(2):89.
[3] Siegel R, Ma JM, Zou ZH, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
[4] Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update[J]. CA Cancer J Clin, 2015, 65(5):401-421.
[5] Hamakawa H, Nakashiro K, Sumida T, et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer[J]. Head Neck, 2008, 30(6):800-809.
[6] Harvey KF, Zhang XM, Thomas DM. The Hippo pathway and human cancer[J]. Nat Rev Cancer, 2013, 13(4):246-257.
[7] Pan DJ. The hippo signaling pathway in development and cancer[J]. Dev Cell, 2010, 19(4):491-505.
[8] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J for Clin, 2017, 67(1):7-30.[LinkOut]
[9] Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: analysis of the national cancer database 1998-2006[J]. Oral Oncol, 2016, 52: 45-51.
[10] 张斌. 口腔鳞状细胞癌的表观遗传学研究现状和进展[J]. 口腔颌面外科杂志, 2016, 26(2):77-82.
[11] Nagumo T, Ito D, Tsukamoto H, et al. STAT3 as a target of molecular targeting therapy for oral cancer: cell-based screening using inhibitor screening kits[J]. Asian J Oral Maxillofac Surg, 2011, 23(4):167-171.
[12] Xiao H, Jiang N, Zhou BY, et al. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma[J]. Cancer Sci, 2015, 106(2):151-159.
[13] Li ZW, Wang YL, Zhu YM, et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer[J]. Mol Oncol, 2015, 9(6): 1091-1105.
[14] Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells[J]Cancer Res, 2008, 68(8):2592-2598.
[15] Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update[J]. Arch Toxicol, 2015, 89(6):867-882.
[16] Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment[J]. Annu Rev Med, 2016, 67(1):11-28.
[17] Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion[J]. Cancer Metastasis Rev, 2009, 28(1-2):15-33.
|